Beyond antipsychotics: Pharmacologically-augmented cognitive therapies (PACTs) for schizophrenia

Neuropsychopharmacology

Volumn 37, Issue 1, 2012, Pages 310-311

  Swerdlow, Neal R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

BRAIN REGION; COGNITIVE THERAPY; EXERCISE; NERVE CELL PLASTICITY; NEUROPATHOLOGY; NEUROPHYSIOLOGY; NOTE; PRIORITY JOURNAL; SCHIZOPHRENIA; WORKING MEMORY;

COGNITIVE THERAPY; COMBINED MODALITY THERAPY; HUMANS; PSYCHOPHARMACOLOGY; PSYCHOTHERAPY; PSYCHOTIC DISORDERS; SCHIZOPHRENIA;

EID: 84856083441     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2011.195     Document Type: Note

References (6)

1. Gottlieb JD, Cather C, Shanahan M, Creedon T, Macklin EA, Goff DC (2011). D-cycloserine facilitation of cognitive behavioral therapy for delusions in schizophrenia. Schiz Research 131: 69-74.
2. Javitt DC, Spencer KM, Thaker GK, Winterer G, Hajos M (2008). Neurophysiological biomarkers for drug development in schizophrenia. Nat Rev Drug Discov 7: 68-83.
3. McGurk SR, Twamley EW, Sitzer DI, McHugo GJ, Mueser KT (2007). A meta-analysis of cognitive remediation in schizophrenia. Am J Psychiatry 164: 1791-1802. (Pubitemid 351739231)
4. Ressler KJ, Rothbaum BO, Tannenbaum L, Anderson P, Graap K, Zimand E et al (2004). Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear. Arch Gen Psychiatry 61: 1136-1144. (Pubitemid 39463415)
5. Swerdlow NR (2011). Are we studying and treating schizophrenia correctly? Schiz Res 130: 1-10.
6. Wykes T, Steel C, Everitt B, Tarrier N (2008). Cognitive behavior therapy for schizophrenia: effect sizes, clinical models, and methodological rigor. Schizophr Bull 34: 523-537.